Artwork

Contenu fourni par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Player FM - Application Podcast
Mettez-vous hors ligne avec l'application Player FM !

Episode 12. ASH 2022 Myeloma Recap

1:02:43
 
Partager
 

Manage episode 350928267 series 3369804
Contenu fourni par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma

https://ash.confex.com/ash/2022/webprogram/Paper159606.html

https://ash.confex.com/ash/2022/webprogram/Paper168930.html

2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.

https://ash.confex.com/ash/2022/webprogram/Paper170166.html

Link to the model: https://istopmm.com/riskmodel/

3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma

https://ash.confex.com/ash/2022/webprogram/Paper159357.html

4. Talquetamab: Phase 1/2 results from Monumental-1

https://tinyurl.com/kwn9en9m

https://www.nejm.org/doi/full/10.1056/NEJMoa2204591

5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosis

https://tinyurl.com/yrvjjruv

6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myeloma

https://tinyurl.com/bde84xuw

7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

https://ash.confex.com/ash/2022/webprogram/Paper159711.html

8. Three excellent abstracts from IstopMM:

Is MGUS associated with autoimmune disease?

https://tinyurl.com/5dafcz2w

Is isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?

https://tinyurl.com/4tut3rea

Is MGUS associated with CKD?

https://tinyurl.com/34swvkj9

9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trials

https://tinyurl.com/2n78yzfh

10. Surrogacy between PFS and OS in Multiple Myeloma

https://ash.confex.com/ash/2022/webprogram/Paper163855.html

https://pubmed.ncbi.nlm.nih.gov/36495317/

  continue reading

48 episodes

Artwork
iconPartager
 
Manage episode 350928267 series 3369804
Contenu fourni par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

1. GEM-CESAR and ASCENT Trials: Intensive Treatment Strategy in High-Risk Smoldering Multiple Myeloma

https://ash.confex.com/ash/2022/webprogram/Paper159606.html

https://ash.confex.com/ash/2022/webprogram/Paper168930.html

2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.

https://ash.confex.com/ash/2022/webprogram/Paper170166.html

Link to the model: https://istopmm.com/riskmodel/

3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma

https://ash.confex.com/ash/2022/webprogram/Paper159357.html

4. Talquetamab: Phase 1/2 results from Monumental-1

https://tinyurl.com/kwn9en9m

https://www.nejm.org/doi/full/10.1056/NEJMoa2204591

5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosis

https://tinyurl.com/yrvjjruv

6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myeloma

https://tinyurl.com/bde84xuw

7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

https://ash.confex.com/ash/2022/webprogram/Paper159711.html

8. Three excellent abstracts from IstopMM:

Is MGUS associated with autoimmune disease?

https://tinyurl.com/5dafcz2w

Is isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?

https://tinyurl.com/4tut3rea

Is MGUS associated with CKD?

https://tinyurl.com/34swvkj9

9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trials

https://tinyurl.com/2n78yzfh

10. Surrogacy between PFS and OS in Multiple Myeloma

https://ash.confex.com/ash/2022/webprogram/Paper163855.html

https://pubmed.ncbi.nlm.nih.gov/36495317/

  continue reading

48 episodes

모든 에피소드

×
 
Loading …

Bienvenue sur Lecteur FM!

Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.

 

Guide de référence rapide